Assembly Biosciences ASMB
Assembly Biosciences FY 2020: net loss $62.2M
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001564590-21-008878
- Document
- 10-K
- Exhibit 4.3
- Warrants or notes
- Exhibit 10.11
- Material contract
- Exhibit 10.12
- Material contract
Key figures from this report
These are the numbers Assembly Biosciences reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$62.2MNo year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$59.4MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$63.0MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Milestone Pharmaceuticals MIST public float $99M, Jun 30, 2025
- DiaMedica Therapeutics DMAC public float $96M, Jun 30, 2025
- Larimar Therapeutics LRMR public float $95M, Jun 30, 2025
- Ironwood Pharmaceuticals IRWD public float $103M, Jun 30, 2025
- Vaxart VXRT public float $103M, Jun 30, 2025